Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Cibc World Markets Corp bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the fourth quarter, ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

The biotech industry may be cooling off, but there’s still plenty to be excited about when it comes to the underlying ...

IFF Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.